Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone

Inclusion Criteria: * Intermittent claudication. * A systolic ankle brachial index ABI \< 0. 9 * An age of over 40 years * At least one cardiovascular risk factor (active or weaned Smoking, diabetes mellitus, hypertension, lipid disorders, obesity, and erectile dysfunction) or a history of coronary artery disease or transient ischemic stroke or established. * Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: * withdrawal of informed consent * participation in another clinical trial with investigational drugs within the last 12 weeks or during the present trial period * history of hypersensitivity to the investigational/conventional drugs * Non claudicating patients and patients with critical ischemia * Arteritis of non-atherosclerotic origin * Patients treated with the oxalate or Naftidrofuryl Pentoxifiline Cilostazol or within 3 months that preceded the inclusion * Patients receiving other agents that alter the secretion of NO (such as Sildenafil and Tadalafil) less than 2 weeks before inclusion * Patients receiving a regimen based on nitrates or molsidomine or Bosentan * Patients receiving Anti Vitamin K medication (AVK) * Hemorrhagic accident dating less than 15 days before inclusion * Heparin treatment or any treatment by low molecular weight heparins during the study for a continuous period of more than 10 days or a cumulative time during the study for more than 21 days.